Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
101. |
ECCT/16/11/02 | IMPAACT P1093 Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and AdolescentsPhase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents |
Principal Investigator(s) 1. Lucy Koech Site(s) in Kenya KENYA MEDICAL RESEARCH INSTITUTE/WALTER REED PROJECT HIV PROGRAME |
28-03-2017 |
View |
102. |
ECCT/16/10/02 | PAINT Study A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years |
Principal Investigator(s) 1. Professor Walter Jaoko Site(s) in Kenya 1. KAVI Institute of Clinical Research (Nairobi City county) 2. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county) |
13-02-2017 |
View |
103. |
ECCT/16/08/03 | IMPAACT 2001 A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection |
Principal Investigator(s) 1. Deborah Chepngeno Langat Site(s) in Kenya Kenya Medical Research Institute Walter Reed project |
27-10-2016 |
View |
104. |
ECCT/16/07/05 | HESTIA 1 Multicentre, open-label, randomised, pharmacokinetic (PK) and pharmacodynamic (PD) dose-ranging Phase II study of ticagrelor followed by a double-blind, randomised, parallel-group, placebo-controlled 4 weeks extension phase in paediatric patients with sickle cell disease |
Principal Investigator(s) 1. Jessie Nyokabi Githanga 2. Videlis Nduba 3. Bernhards Ragama Ogutu Site(s) in Kenya 1. Gertrude’s Children’s Hospital (Nairobi City county) 2. Kemri CRDR research center at Chandaria Health Centre Dagoretti (Nairobi City county) 3. Clinical Research Annex at the Siaya County Referral Hospital (Siaya county) 4. Kondele Children’s Hospital, KEMRI – Centre for Clinical Research (Kisumu county) |
19-09-2016 |
View |
105. |
ECCT/16/06/01 | P1115 Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study |
Principal Investigator(s) 1. Fredrick Sawe Site(s) in Kenya KEMRI WALTER REED PROJECT KERICHO |
25-07-2016 |
View |
106. |
ECCT/16/05/01 | A5338 A5338 An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz (EFV) in Women Co-Infected with Human Immunodeficiency Virus (HIV) and Tuberculosis (TB) |
Principal Investigator(s) 1. David Schnabel Site(s) in Kenya KISUMU CRS |
28-07-2016 |
View |
107. |
ECCT/16/05/03 | Clinical trial of neem & coconut oils for tungiasis Phase IIA, randomised controlled trial of a locally-made, herbal remedy (neem & coconut oil) for treatment of jiggers (Tunga penetrans) |
Principal Investigator(s) 1. Ulrike Fillinger Site(s) in Kenya Dabaso Tujengane CBO |
28-03-2017 |
View |
108. |
ECCT/16/04/01 | HVTN 703/HPTN 081 Protocol A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection HVTN 703/HPTN 081 A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection |
Principal Investigator(s) 1. Dr. Victor Akelo Akelo Site(s) in Kenya KISUMU CRS |
14-07-2016 |
View |
109. |
ECCT/16/02/06 | A study of the safety and immune response of 2 doses of a new Shigella vaccine in Kenyan adults. A Phase 2a, observer blind, randomized, controlled, Single Center Study to evaluate the Safety, Reactogenicity and Immunogenicity of 2 doses of the GVGH 1790GAHB Vaccine against Shigella sonnei, administered intramuscularly in Adult Subjects from a country endemic for shigellosis [GVGH study H03_04TP] |
Principal Investigator(s) 1. Christina Wesonga Obiero Site(s) in Kenya Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme |
15-04-2016 |
View |
110. |
ECCT/16/03/02 | Infant TB Infection Prevention Study (“iTIPSâ€) Preventing Mycobacterium Tuberculosis Infection in HIV-Exposed Infants |
Principal Investigator(s) 1. Grace John-Stewart Site(s) in Kenya 1. Kisumu East District Hospital (Kisumu county) 2. Ahero County Hospital (Kisumu county) 3. Bondo sub-County Hospital (Kisumu county) |
03-06-2016 |
View |